After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here. Merck ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Yes, Java certification is still worth it, but it pays to know which ones will help you stand out. Here's what you need to know about Java course certificates and hiring in 2025. Java, which turns 30 ...

Language is often considered the hallmark of human intelligence, a complex system that enables us to share thoughts, express emotions, and convey intricate messages. For years, scientists believed ...

Hello there! 👋 I'm Luca, a BI Developer with a passion for all things data, Proficient in Python, SQL and Power BI ...

Altitude Labs, a biotechnology accelerator backed by Recursion Pharmaceuticals, on Wednesday said it is launching a new fund to give pre-seed grants to life sciences researchers and startups disrupted ...